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in human glioblastoma cells
Dongdong Chen1, Mingke Song1, Osama Mohamad1 and Shan Ping Yu1,2*Abstract
Background: Glioblastoma multiforme (GBM) is very difficult to treat with conventional anti-cancer/anti-apoptotic
drugs. We tested the hypothesis that inhibition of Na+/K+-ATPase causes a mixed or hybrid form of concurrent
apoptosis and necrosis and therefore should enhance anti-cancer effects of chemotherapy on glioblastoma cells.
Methods: In human LN229 and drug-resistant T98G glioblastoma cell cultures, cell death and signal pathways were
measured using immunocytochemistry and Western blotting. Fluorescent dyes were applied to measure intracellular
Ca2+, Na+ and K+ changes.
Results: The specific Na+/K+-ATPase blocker ouabain (0.1 - 10 μM) induced cell death and disruption of K+ homeostasis
in a time- and concentration-dependent manner. Annexin-V translocation and caspase-3 activation indicated an
apoptotic component in ouabain cytoxicity, which was accompanied with reduced Bcl-2 expression and mitochondrial
membrane potential. Ouabain-induced cell death was partially attenuated by the caspase inhibitor Z-VAD (100 μM).
Consistently, the K+ ionophore valinomycin initiated apoptosis in LN229 cells in a K+ efflux-dependent manner. Ouabain
caused an initial cell swell, which was followed by a sustained cell volume decrease. Electron microscopy revealed
ultrastructural features of both apoptotic and necrotic alterations in the same cells. Finally, human T98G glioblastoma
cells that are resistant to the chemotherapy drug temozolomide (TMZ) showed a unique high expression of the
Na+/K+-ATPase α2 and α3 subunits compared to the TMZ-sensitive cell line LN229 and normal human astrocytes. At
low concentrations, ouabain selectively killed T98G cells. Knocking down the α3 subunit sensitized T98G cells to TMZ
and caused more cell death.
Conclusion: This study suggests that inhibition of Na+/K+-ATPase triggers hybrid cell death and serves as an
underlying mechanism for an enhanced chemotherapy effect on glioblastoma cells.
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Glioblastoma multiforme (GBM), also called glioblastoma,
is the most common and aggressive primary brain tumor
in adults. It is classified as a Grade IV brain tumor ac-
cording to the World Health Organization (WHO)
classification. Due to its aggressive biological behavior,
diffuse infiltrative growth and central location, it has
become one of the most challenging cancers of the* Correspondence: spyu@emory.edu
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unless otherwise stated.central nervous system (CNS) [1,2]. The therapeutic
approach to glioblastoma includes maximal safe resection
surgery followed by radiation therapy plus concomitant
and adjuvant chemotherapy [1,3]. Glioblastoma often show
little to no response to conventional anti-cancer drugs
such as temozolomide (TMZ) and it becomes resistant
to apoptosis after a short period of treatment. This is
especially true for invasive malignant glioma cells that are
resistant to pro-apoptotic chemotherapy and radiotherapy
[4-6]. The current 5-year overall survival of grade IV
GBM patients using radiotherapy with concomitant TMZ
treatment is only 9.8%. The resistance to chemotherapytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment of cancer, especially in GBM patients.
Tumor-induced hypoxic barriers, existence of cancer
stem cells, enhanced membrane transporter activities
and other mechanisms may be important factors in drug
resistance [7]. One way in which cancer cells can achieve
resistance to anti-cancer drugs is by up-regulating the
ATP-binding cassette transporter proteins which are
responsible for the efflux of anti-cancer molecules from
the intracellular compartment [8]. Another mechanism
of resistance to chemotherapy involves the hypoxic
conditions in the central portions of the tumor and the
resultant over-expression of HIF-1α that enhances a
cell’s tolerance to insults including anti-cancer drugs.
Furthermore, hypoxic cells may be less proliferative
and thus less responsive to anti-cancer drugs that target
rapidly proliferating cells [9]. We hypothesize that a new
therapeutic approach that can simultaneously trigger
more than one cell death program/mechanism may
have a better chance of overcoming the drug resistance
of glioblastoma cells.
Na+/K+-ATPase, also known as the Na+ pump or more
accurately the Na+/K+ pump, is a ubiquitously expressed
transmembrane transporter composed of tetramers of alpha
and beta subunits. A normal activity of Na+/K+-ATPase is
essential for maintaining ionic homeostasis, cellular pH,
and cell volume [10]. The catalytic alpha subunit is a large
polypeptide of ~1,000 amino acid residues, which catalyzes
the ion-dependent ATPase activity and carries the binding
sites for ATP and the specific inhibitor ouabain. The beta
subunit is a smaller polypeptide of about 300 residues,
which regulates conformational stability and activity of the
alpha subunit. The Na+/K+ pump is critical in maintaining
high extracellular Na+ (~145 mM) and high intracellular
K+ (~150 mM) by pumping Na+ ions out of the cell and
importing K+ ions into the cell [11]. By doing so, these
Na+/K+ pumps maintain a physiological electrochemical
gradient that is essential for cell survival and for many
cellular activities. Consistent with its pro-life role,
Na+/K+-ATPase is highly expressed in cancer cells in-
cluding glioblastoma cells [12-14]. The Na+/K+ pump
activity increases during the course of malignant cell
transformation [15]. This increased expression and ele-
vated activity suggest that Na+/K+-ATPase may serve as
a biological marker and a therapeutic target of cancer
cells. Along with the identification of its high expression
in cancer cells and its critical roles in cell survival, pro-
liferation, adhesion and migration, the clinical potential
of Na+/K+-ATPase modulators such as cardiotonic ste-
roids or digitalis in oncology has drawn increasing at-
tention in recent years [12,16]. Several cardenolides
have been shown to display in vitro antitumor activities
against various types of cancer cells [17-21], including
glioma cells [22,23].Cardiac glycosides including digoxin, marinobufagenin,
telocinobufagin and ouabain, represent a group of com-
pounds isolated from plants and animals [24]. Endogenous
ouabain-like substances were also identified as a hormone
or stress signal that responds to exogenous and endogen-
ous stimuli such as physical exercise, stress, hypertension,
hypoxia/ischemia, among many others [24]. These cardiac
glycosides have been used in clinical therapies of heart
failure and atrial arrhythmia for many years [19,24].
Meanwhile, digoxin acts as a specific neuroblastoma
growth inhibitor in mice grafted with the neuroblast-
oma cell lines SH-SY5Y and Neuro-2a [25]. Blocking
Na+/K+-ATPase using the exogenous cardiac glycoside
ouabain is cytotoxic to a variety of cancer and non-
cancerous cells; the sensitivity depends on the expres-
sion level of the functional Na+/K+ pump and dosage
used [26-29]. Ouabain and the specific knockdown of
the Na+/K+-ATPase alpha subunit inhibits cancer cell
proliferation and migration [13,22], sensitizes resistant
cancer cells to anoikis and decreases tumor metastasis
[30]. However, the cellular/molecular mechanisms under-
lying the cytotoxic effect of cardiac glycosides in tumor
cells have been poorly defined. We noticed that blocking
Na+/K+-ATPase has two direct and marked impacts on
the cellular ionic homeostasis: increased intracellular
Na+ concentration and decreased intracellular K+ con-
centration. The majority of previous studies have been
focused on the intracellular Na+ increase and the conse-
quent intracellular Ca2+ increases due to the enhanced
reversal operation of the Na+-Ca2+ exchanger [31-33].
On the other hand, increasing evidence from our groups
and other’s have demonstrated that, in many noncancer-
ous neuronal and non-neuronal cells, depletion of intra-
cellular K+ is a prerequisite for apoptotic cell shrinkage,
activation of caspases and initiation of apoptotic pro-
graming [34-36]. Consistently, attenuating the outward
K+ current with tetraethylammonium or elevating extra-
cellular K+ prevented apoptosis while treatment with the
K+ ionophore valinomycin induced apoptosis [37,38],
There is also evidence that cytosolic Ca2+ levels may not
directly regulate apoptotic cell death [11,39]. Therefore,
besides the regulation by a series of apoptotic genes,
apoptosis is regulated by an ionic mechanism closely
associated with K+ homeostasis [11,39,40]. Up to now,
little attention has been paid to the intracellular K+ loss
in cancer cells.
We previously demonstrated in different noncancerous
cells that inhibition of Na+/K+-ATPase induced a mixed
form of cell death composed of concurrent necrotic and
apoptotic components in the same cells, which we named
hybrid death [41]. Specifically, the increases in intracellu-
lar Na+ and Ca2+ are associated with necrosis and K+ de-
pletion is linked to apoptosis. These events may take
place simultaneously and trigger activation of multiple
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was also based on cellular/sub-cellular morphological
changes, gene expression, and alterations in intracellular
signaling pathways [11,41].
In this investigation, we tested the main hypothesis
that inhibition of Na+/K+-ATPase could disrupt K+ and
Na+/Ca2+ homeostasis and subsequently induce hybrid
death in human glioblastoma cells. Ouabain was tested
because of its high selectivity in blocking NA+/K+-ATPase.
We also tested whether inhibition of Na+/K+-ATPase or
deletion of its specific subunit could enhance the sensitiv-
ity of glioblastoma cells to TMZ in the drug-resistant
T98G glioblastoma cells.
Methods
Cultures of human glioblastoma cells
Human glioblastoma cell lines LN229 and T98G (kindly
supplied by Dr. Erwin G. Van Meir, Emory University,
Winship Cancer Institute) were maintained in Dulbecco’s
modified Eagle’s media supplemented with 10% fetal
bovine serum (FBS).
Ethics statement
LN229 and T98G cells are established cell lines from
glioblastoma of anonymous patients and are commer-
cially available. These cells have been extensively used in
cancer research and related information is publically
available. Therefore, their use was not classified as hu-
man subject research, and no Institutional Review Board
approval was needed.
Cell viability assay by MTT spectrophotometry
Cells were cultured at a density of 3000 cells/well in 96-
well plates at 5% CO2 and 37 °C. At 70% confluence,
cells were treated with either ouabain or other drugs. At
selected time points, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-di-
phenyltetrazolium (MTT) was added at a final concen-
tration of 0.5 mg/mL. After 4 hrs incubation, the
reaction was stopped by adding a solubilization buffer
(10% SDS, 10 μM HCl). After the mixture was incubated
at 37°C for 2 hrs, the relative optical density for each
well was determined at 570 nm by a microplate spectro-
photometer (Bio-Tek, Winooski, Vermont).
Apoptosis detection by flow cytometry
Phosphatidylserine (PS) membrane translocation and
caspase-3 activation were determined by flow cytometry
using FITC Annexin V Apoptosis Detection Kit (BD
Pharmingen, San Diego, CA). Cells were treated with
1 μM ouabain or 10 μM valinomycin for selected time
points and then washed twice with phosphate-buffered
saline (PBS). Staining procedures followed the standard
protocol provided by the manufacturer. Briefly, 1 × 106
cells were resuspended in 1 mL of binding buffer andthen the 100 μL cell suspension was incubated with
1 μL Annexin-V-FITC and 1 μL propidium iodide (PI)
for 15 min at room temperature in the dark. Propidium
iodide was used as a marker of necrosis. The population of
Annexin V-positive cells was evaluated by a BD Biosciences
LSR II flow cytometer and analyzed by FlowJo Version 7.6
software (Tree Star, Ashland, OR).
Western blotting analysis
Cells were lysed in protein lysis buffer (25 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 2 mM
sodium orthovanadate, 100 mM NaF, 1% Triton, leupep-
tin, aprotinin, and pepstatin) containing protease inhibitor
(Sigma, St Louis, MO). Protein concentration was deter-
mined using the Bicinchoninic Acid Assay (Sigma). 30 μg
protein samples were separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) in a Hoefer Mini-Gel
system (Amersham Biosciences, Piscataway, NJ) and
transferred onto a PVDF membrane (BioRad, Hercules,
CA). The blotting membrane was incubated with pri-
mary antibodies overnight: Bcl-2 and cleaved Caspase-3
(1:1000, Cell Signaling, Danvers, MA), Cytochrome c
and Caspase-9 (1:500, Millipore, Billerica, MA), β-actin
(1:5000, Sigma). The blots were incubated for 1 hr at
room temperature with anti-mouse or anti-rabbit alkaline
phosphatase-conjugated IgG antibodies (1:2000, Promega,
Madison, WI). The signals were detected by the addition
of 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetra-
zolium (BCIP/NBT) solution (Sigma) and quantified
and analyzed by the NIH imaging software Image J
(NIH, Bethesda, MD). The level of protein expression
was normalized to β-actin controls. The value of protein
levels was designed as 1 in the control group. The results
were expressed as mean proportion of the control group
values.
Immunocytochemistry staining
Cells were fixed with 4% paraformaldehyde and then
treated with 0.2% Triton-X 100 for 5 min. After blocking
with 1% fish gel for 1 hr, cells were incubated with primary
anti-body AIF overnight (1:500, Millipore). Cells were
then incubated with secondary antibody Cy3-conjugated
anti-rabbit IgG (1:500, Invitrogen, Carlsbad, CA) for 1 hr
at room temperature. Nuclei were stained with Hoechst
33342 (1:20000, Invitrogen). Staining was visualized by
fluorescent and confocal microscopy (BX61; Olympus,
Japan).
Fluorescent measurement of the mitochondrial
membrane potential
Cells were treated with ouabain or valinomycin for 6 hrs
and then loaded with 200 nM TMRM (Molecular Probes,
Eugene, OR) for 30 min at 5% CO2 and 37°C in the dark.
Prior to imaging, cells were washed with DMEM medium
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microscope (Leica DMIRB, Germany) and fluorescent
intensity was measured by the NIH imaging software
Image J.
Cellular ion measurements
Intracellular K+ content was measured using the cell
permeant potassium indicator PBFI-AM (Invitrogen,
Molecular Probes). Cells were washed with HBSS and
then loaded with 5 μM PBFI and 10 μM F-127 for 40 min
at 5% CO2 and 37°C in the dark. Cells were washed with
HBSS three times before imaging. Measurements were
made by exciting PBFI at 340 nm while monitoring emis-
sion at 500 nm using a fluorescent microscope (Leica
DMIRB, Germany) and the fluorescence intensity was
measured using the NIH imaging software Image J.
Intracellular Na+ content was measured using the
cell permeant sodium indicator SBFI-AM (Invitrogen,
Molecular Probes). Cells were washed with HBSS and
then loaded with 5 μM SBFI and 10 μM F-127 for
40 min at 5% CO2 and 37 °C in the dark. After three
HBSS washes, fluorescent imaging was carried out at
room temperature using an inverted fluorescence micro-
scope (Olympus IX81, Olympus America Inc., Center
Valley, PA). Measurements were made by exciting SBFI
at 340 nm while monitoring emission at 520 nm using a
CCD camera. The imaging data were recorded with a
digital camera Hamamatsu ORCA-ER (Hamamatsu
Photonics K.K., Japan) and software Slidebook 4.1 for
Windows (SciTech Pty Ltd., Australia).
Intracellular free Ca2+ was measured using the cell
permeate Ca2+ sensitive dye Fluo-4-AM (Invitrogen; 5 μM
in 100 μl HEPES buffered solution) for 50 min at 5% CO2
and 37°C in the dark. Fluo-4 epifluorescence was excited
at 480 nm light and images were obtained at 520 nm. The
imaging data were collected by the same fluorescence mi-
croscopy system described for sodium imaging.
Cell volume assay
Cells were trypsinized after drug treatments. A 100 μL
cell suspension of each sample was taken by Millipore
Scepter™ Handheld Automated cell counter (Millipore).
Cell volume was measured and analyzed by Scepter Soft-
ware Pro 2.0.
Electron microscopic examination of ultrastructural
changes
Cultures in 35 mm dishes were fixed in glutaraldehyde
(1% glutaraldehyde, 0.1 M sodium cacodylate buffer,
pH 7.4) for 30 min at 4 °C, washed with 0.1 M sodium
cacodylate buffer, and post-fixed in 1.25% osmium tetrox-
ide for 30 min. The staining and electron microscopy was
performed at the Robert P. Apkarian Integrated Electron
Microscopy Core (Emory University, Atlanta, GA).Cytochrome c release assay
Cells were harvested by centrifugation at 200 g for 10 min
at 4°C. Mitochondrial and cytoplasmic proteins were
isolated using the Mitochondria Isolation Kit (Thermo
Scientific, Rockford, IL) according to the kit’s instruc-
tions. Cytochrome c released from the mitochondria
was detected by Western blot.
Knockdown of the Na+/K+-ATPase α3 subunit
Na+/K+-ATPase α3 stealth RNAi™ siRNA duplex oligori-
bonucleotides were synthesized by Invitrogen. The se-
quences of the siRNA duplex were designed by Invitrogen
Block-iT RNAi Designer:
Forward: 5′-ACG ACA ACC GAU ACC UGC UGG
UGA U-3′
Reverse: 5′-AUC ACC AGC AGG UAU CGG UUG
UCG U-3′
The T98G cells were transfected with Na+/K+-ATPase
α3 stealth RNAi™ siRNA or stealth RNAi™ siRNA negative
control (Invitrogen) using Lipofectamine™ 2000 (Invitro-
gen) according to the manufacture’s instruction. Briefly,
0.5 × 105 T98G cells were plated in a 6-well plate and
cultured overnight. 250 pmol siRNA duplex or siRNA
negative control was mixed with 10 μL lipofectamine
reagent in the serum free Opti-MEM medium and trans-
fected the T98G cells for 6 hrs. 48 hrs later, the cells were
harvested for the reverse transcriptase-polymerase chain
reaction (PCR) to detect the expression of the α3 subunit.
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from human glioblastoma cells
using the Trizolreagent (Invitrogen) according to the
procedure suggested by the manufacturer. For cDNA
synthesis, 1 μg of total RNA were reverse transcribed into
cDNA using RNA to cDNA High Capacity kit (Invitrogen)
and PCR was performed in a PTC-150 Minicycler (MJ
Research Inc., Watertown, MA) with primer sets for
target genes and a housekeeping gene, ribosomal protein
large subunit 19 (RPL19) as an internal control for both
cDNA quantity and quality. PCR primers, as listed below,
were designed according to the sequences in a previous
report [42]. All the primers were designed to amplify
products that covered one or more exons.
Na+/K+-ATPase á1 forward 5′-GAA AGA AGT TTC
TAT GGA TG-3′
reverse 5′-ATG ATT ACA ACG GCT GAT AG-3′
Na+/K+-ATPase á2 forward 5′-AGA GAA TGG GGG
CGG CAA GAA G-3′
reverse 5′-TGG TTC ATC CTC CAT GGC AGC C-3′
Na+/K+-ATPase á3 forward 5′-CCT CAC TCA GAA
CCG CAT GAC-3′
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RPL19 forward 5′-GAG TAT GCT CAG GCT TCA
GA-3
reverse 5′-TTC CTT GGT CTT AGA CCT GC-3′
After an initial phase at 94°C for 2 min, amplification
of α1 was run for 31 cycles and α 2 and α 3 for 40 cycles.
The cycles consisted of denaturation at 94°C for 1 min,
annealing at 50°C for 45 s for α 1 and 54°C for 1 min for
α 2 and α 3, extension at 72°C for 1 min, and a final
extension of 7 min at 72°C at the end of the program.
The PCR products (25 μL) in TAE buffer were loaded
onto 1.5% agarose gel and run at 36 V for 90 min. The
Gel was scanned for quantitative analysis using the
UnScan It program (Silk Scientific Inc., Orem, UT).
The ratio of target gene to housekeeping gene, RPL19,
was calculated.
Chemicals
The caspase inhibitor Z-VAD-FMK was purchased from
Enzyme Systems Products [42]. BAPTA-AM was from
Tocris Bioscience (Bristol, UK). Ouabain and valinomycin
were from Sigma Aldrich (St. Louis, MO) [42].
Statistical analyses
One-way ANOVA followed by Tukey post-test was per-
formed for multiple group comparisons. Two-way ANOVA
followed by Bonfferoni post-tests was used for multiple
groups with multiple time points. Data were shown as
mean ± SEM. Changes were identified as significant if
p value was less than 0.05.
Results
Ouabain-induced cell volume changes and toxicity in
LN229 cells
Exposure of glioblastoma LN229 cells to ouabain caused
noticeable morphological changes including cell swelling
and, as a sign of membrane deterioration, granule struc-
tures started to appear on the surface of the cell membrane
(Figure 1A). A quantified analysis revealed that the cell
swelling developed soon after exposure to ouabain (1 μM)
and reached the peak around 3–6 hrs later (Figure 1B-C).
Interestingly, the swollen cells gradually returned to the
original size regardless of the continuous presence of oua-
bain in the medium (Figure 1B-C). Moreover, raising the
extracellular K+ concentration from 5 to 25 mM showed
no effect on cell swelling but prevented the belated cell
volume reduction, implying that a K+ efflux mechanism
mediated the cell volume decrease (Figure 1C).
As an initial test for ouabain induced cytotoxicity in
human glioblastoma cells, we exposed LN229 cultures to
different ouabain concentrations. The MTT assay showed
that ouabain induced time- and concentration-dependent
cell viability reduction in these cells (Figure 1D). At a lowconcentration of 0.1 μM that is sublethal to normal neur-
onal cells [43], ouabain caused 13.8%, 23.9% and 42.0% re-
duction in cell viability after 6-, 24- and 48-hr exposures,
respectively. Increasing ouabain concentration from 0.1 to
1 μM significantly augmented the cytotoxic effect at all
time points (Figure 1D). Even higher concentrations
(2 and 5 μM) did not further increase the toxicity at
24 to 48 hrs (Figure 1D). In the following experiments,
1 μM ouabain was selected to produce toxic effect in
LN229 cells.Ouabain-induced activation of apoptotic cascade in
LN229 cells
The translocation of phosphatidylserine (PS) from the
cytoplasmic side of the plasma lipid membrane to the
membrane outer surface is an early event in apoptosis.
Annexin V has been widely used as a probe for detecting
this PS translocation event. Ouabain-induced PS trans-
location in LN229 cells was inspected using flow cytom-
etry. Annexin V-positive cells significantly increased
after a 5-hr exposure to ouabain (1 μM) (Figure 2A).
Meanwhile, ouabain treatment for 3 hrs significantly in-
creased activation of caspase-3 and caspase-9 (Figure 2).
The activation of caspases was also detected using
Western blot analysis (Figure 2C to E). Maximal activa-
tion of both caspases-3 and caspase-9 occurred 3 hrs
after ouabain treatment and then dropped to control levels
after 24 hrs. The anti-apoptotic protein Bcl-2 expression
was reduced 24 hrs after ouabain treatment (Figure 2F).
In line with the apoptotic component in ouabain-induced
death of LN229 cells, co-applied caspase pan inhibitor
Z-VAD-FMK (100 μM) significantly attenuated the
ouabain-induced cell death (Figure 2). There was a cell
death component, however, that was not prevented by
the high concentration of Z-VAD (IC50 ≤ 10 uM for caspase
inhibition), suggesting that there were caspase-independent
cell death mechanisms in ouabain cytotoxicity yet to be
identified.Ouabain-induced loss of mitochondrial membrane
potential in LN229 cells
The loss of mitochondrial membrane potential is an
early event indicating dysfunction of energy metabol-
ism and cell damage associated with both apoptosis
and necrosis [44-47]. Tetramethylrhodamine methyl
ester (TMRM) is a cell membrane permeable cationic
dye that is actively sequestered by live mitochondria
and has been used to detect changes in mitochondrial
membrane potential [48]. In LN229 cells, 6-hr exposure to
1 μM ouabain caused a marked decrease in orange-red
fluorescence of TMRM, indicating a significant loss of
mitochondrial membrane potential and damage to the
cells (Figure 3A and B).
Figure 1 Ouabain-induced cell volume changes and cytotoxicity in LN229 cells. Oubain-induced cell volume changes and toxicity were
inspected in LN229 cell cultures to delineate the time- and concentration-dependent consequences of blocking Na+/K+-ATPase. A. Phase contrast
images showing morphological changes of LN229 cells during 6 to 24 hrs exposures to ouabain (1 μM). B. Cell volume distributions examined
using a Millipore ScepterTM Handheld Automated cell counter illustrated a dynamic cell volume regulation during 24-hr exposure to ouabain
(1 μM). A transient but noticeable cell swelling was seen at 3 and 6 hrs after ouabain treatment, while the cell volume returned to the original size
after 12 to 12 hrs in ouabain. C. Cell volume changes were assessed and compared between ouabain (1 uM) in normal medium containing
5 mM K+ and ouabain exposure in an elevated K+ medium (25 mM KCl). Although cells exposed to ouabain in normal medium returned to their
original sizes after 24-hr exposure, the ouabain exposure in the high K+ medium eliminated the cell shrinking phase. D. The time- and
concentration-dependent cytotoxic effects of ouabain in LN229 cultures. Cell viability was measured using the MTT assay. In general, the
longer the exposure time, the lower cell viability was induced by ouabain. Increasing ouabain concentration from 0.1 μM to 1 μM induced
further reduction in cell viability. Even higher ouabain concentrations (2 and 5 μM) showed no further increase in toxic effect. Three
independent experiments and each group in an experiment contained 3–4 duplicates.
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homeostasis and its relation to apoptotic events
The disruption of K+ homeostasis has been linked to ini-
tiation of an apoptotic cascade in many non-cancer cells
[11,34-36,39,40]. To detect whether the K+-mediated
mechanism might contribute to ouabain-induced cell
death in human glioblastoma cells, we measured the
intracellular K+ content using the cell permeable K+
indicator PBFI-AM. As a control, we first treated
LN229 cells with the K+ ionophore valinomycin that iswell known for its highly specific selectivity for K+ flux
through lipid membranes down the K+ electrochemical
gradient [38]. As expected, valinomycin (10 μM) induced
a dramatic depletion of intracellular K+, significant loss of
the mitochondrial membrane potential, and noticeable cell
shrinkage in LN229 cells (Figure 4). The PBFI fluorescent
intensity dropped significantly at 6 hrs after ouabain treat-
ment and continued dropping at 12 and 24 hrs. Thus,
ouabain treatment resulted in a marked and continuous
depletion of intracellular K+ that lasted for many hours,
Figure 2 Ouabain-induced caspase-dependent apoptosis in LN229 cells. Ouabain-induced cell death and apoptotic signaling were evaluated
using flow cytometry and Western blot analysis. A. Flow cytometry results showed that ouabain treatment (1 μM, 5 hrs) increased early (Q3 quadrant)
and late apoptotic (Q2 quadrants) cell populations. N = 3 independent assays. B, C, and D. Western blot analysis revealed that ouabain treatment of
3 hrs induced significant activation of caspase-3 and caspase-9 in LN229 cells. The caspase activations subsided thereafter. E. Western blotting indicated
that although the anti-apoptotic gene Bcl-2 showed a trend of increasing at an early stage during ouabain exposure, the Bcl-2 level significantly
decreased 24 hs after ouabain treatment. N = 3 in each group. F. Ouabain-induced cell death in LN229 cells was partially blocked by co-applied
caspase inhibitor Z-VAD (100 uM). Cell death was measured using the MTT assay. Three independent experiments and each group in an
experiment contained 3–4 duplicates. * P < 0.05 vs. control (CTL).
Chen et al. BMC Cancer 2014, 14:716 Page 7 of 15
http://www.biomedcentral.com/1471-2407/14/716leading to ~50% K+ loss by 24 hrs (Figure 4B). We con-
firmed that valinomycin increased caspase-3 activation
after 6-, 12- and 24-hr exposure, while significant
caspase-9 activation was seen at 12 hrs after valinomy-
cin exposure (Additional file 1: Figure S1 A-C). Mean-
while, the anti-apoptotic protein Bcl-2 expression
decreased at 12 and 24 hrs (Additional file 1: Figure S1
D). Valinomycin also stimulated a nuclear transloca-
tion of the Apoptosis-Inducing Factor (AIF), which
represents a caspase-independent apoptotic pathway
(Additional file 1: Figure S1 E). These tests verified
that, similar to many non-cancerous neuronal and non-
neuronal cells, glioblastoma cells are sensitive to the K+
efflux mediated apoptosis.Supporting the idea that excessive K+ efflux is critical
in apoptotic cell death, attenuating K+ efflux by elevating
extracellular K+ to 25 mM antagonized ouabain-induced
cell death (Figure 4C). To exclude the possibility that
the effect of high K+ medium was mediated via membrane
depolarization associated Ca2+ influx, additional exper-
iments were performed in the presence of the Ca2+
channel blocker nifedipine (1 μM). This maneuver,
however, did not eliminate the protective effect of the
25 mM K+ medium (data not shown, but see [11,41]).
Another important point is that, as in the case with Z-
VAD, the high K+ medium only partially attenuated
ouabain toxicity, confirming there were other injurious
mechanisms in ouabain-induced cell death.
Figure 3 Ouabain and valinomycin induced mitochondrial membrane depolarization in LN229 cells. The mitochondrial membrane
potential was assessed using the fluorescent dye TMRM in LN229 cells. A. TMRM (200 nM) was added into the medium to stain the live cells for
30 min. The intensity of TMRM fluorescence images is a reflection of the mitochondrial membrane potential. The reduction and disappearance of
TMRM staining was seen 6 hrs after ouabain (1 μM) and valinomycin (10 μM) treatment. B. Quantification of TMRM fluorescence intensity after
6 hrs of ouabain treatment. Both ouabain and valinomycin induced a significant loss of the mitochondrial membrane potential in LN229 cells.
DMSO was a vehicle negative control. The fluorescent intensity was quantified using the NIH Image J software. * P < 0.05 vs. controls.
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LN 229 Cells
It is widely accepted that necrosis is triggered by increases
in intracellular Ca2+ and Na+, while blocking the Na+/K+
pump is expected to cause accumulation of intracellular
Na+ and Ca2+. This effect, however, has not been verified
in human glioblastoma cells before. We thus measured
the intracellular Na+ and Ca2+ using the cell permeable
indicators SBFI-AM and Fluo-4-AM, respectively. As
expected, SBFI imaging showed that ouabain increased
intracellular Na+ as early as 5 min after addition of oua-
bain and the effect lasted for up to one hour (Additional
file 2: Figure S2 A and B). Fluo-4-AM Ca2+ imaging
showed that intracellular Ca2+ concentration ([Ca2+]i)
doubled after 3–6 hr treatment with 1 μM ouabain
(Additional file 2: Figure S2 C and D). The [Ca2+]i in-
crease, however, subsided at 24 hrs after ouabain treat-
ment. To determine the role of this [Ca2+]i increase in
ouabain-induced cytotoxicity, the membrane perme-
able Ca2+ chelator BAPTA-AM was added into the
media to prevent the increase in [Ca2+]i. BAPTA-AM
(1 μM) effectively prevented ouabain-induced [Ca2+]i
increases in LN229 cells (Additional file 2: Figure S2).
However, addition of BAPTA-AM did not antagonize
ouabain-induced cell death; rather it showed a trend of
increasing ouabain-induced cell death in MTT assays.
This was likely due to a toxic effect of BAPTA alone on
the survival of LN229 cells (Additional file 2: Figure S2 E).Ouabain-induced ultrastructural changes of hybrid cell
death in glioblastoma cells
Since the morphological changes, especially ultrastructural
ones, have been regarded as a gold standard for distin-
guishing apoptosis from necrosis, we used electron mi-
croscopy to examine the ultrastructural features of
ouabain-induced cell death. Electron microscopy im-
aging revealed that ouabain treatment (1 μM, 24 hrs)
caused breakdown of the plasma membrane, while the
nucleus showed shrinkage in the absence of absolute
cell volume decrease. Cytosol swelling accompanied
the appearance of many empty vacuoles in the cytoplasm
(Figure 5). These subcellular alterations are typical in cells
dying from the hybrid cell death mechanism previously
observed in non-cancerous cells [41,43,49].
High expression of the Na+/K+-ATPase subunits in
glioblastoma cells and its relation to resistance to TMZ
In an effort to understand a possible relationship between
Na+/K+-ATPase and high resistance to chemotherapy
drugs, we examined the expression of Na+/K+-ATPase
subunits α1, α2 and α3 in TMZ-sensitive LN229 cells,
TMZ-resistant T98G cells, as well as normal human as-
trocytes. While T98G cells expressed more α1 mRNA
compared to LN229, the expression of α1 mRNA was not
statistically different from human astrocytes (Figure 6A
and B). It was then interesting to see that T98G cells
expressed higher mRNA levels of the α2 and α3 subunits
Figure 4 Ouabain and valinomycin induced intracellular K+ depletion in LN229 cells. The K+ fluorescent dye PBFI-AM was used to measure
the intracellular K+ changes of LN229 cells during ouabain and valinomycin exposures. A. PBFI images illustrated reduction in intracellular K+ content
24 hrs after ouabain (1 μM) or valinomycin (10 μM) treatment. B. Quantified data of PBFI imaging at 6, 12 and 24 hrs exposures to ouabain and
valinomycin. By 24 hrs after exposure, ouabain and valinomycin each caused aproximatley 50% of cellular K+ loss. This could be equivalent to a
loss of about 70 mM K+ from the intracellular space. DMSO was tested as the vehicle control. N = 180 cells from 3 independent assays in each
group. * P < 0.05 vs. control groups. C. Cell death induced by ouabain was sensitive to a protective effect of high K+ extracellular medium.
Around 50% of cell death was prevented in the high K+ medium. Cell death was measured using the MTT assay 24 hrs after exposure. The
control medium contained 5 mM KCl. # P < 0.05 vs. ouabain group. D. Valinomycin (10 μM) induced cell shrinkage after 3, 6, 12, 24 hrs exposure
in LN229 cells. * P < 0.05 vs. control group.
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unit level was more than doubled in T98G cells compared
to LN229 cells and 4 folds the level in human astrocytes
(Figure 6A to D)
More importantly, T98G cells were more sensitive to
ouabain-induced cell death (0.1 to 5 μM) (Figure 6E),
and were more resistant to TMZ compared to LN229
cells (Figure 6F). It is worth pointing out that the low
concentration of 0.1 μM ouabain does not affect the
viability of LN229 cells, normal astrocytes and non-
cancerous neuronal cells [43], while it showed a signifi-
cant killing effect on T98G cells. Meanwhile, TMZ at
low concentrations induced negligible cell death in
T98G cells, which instead kept proliferating in the
presence of low dose TMZ (Figure 6F). Only when the
TMZ concentration was elevated to 100 μM did T98G
cells show a very mild cell death response (Figure 6F).These data suggested a selective action of ouatain on
TMZ-resistant tumor cells.
In the next experiment, we tested the TMZ killing
effect on T98G and LN229 cells with and without
Na+,K+-ATPase inhibition. At a relatively low dosage
(0.1 μM), ouabain was coapplied with TMZ (100 μM).
This co-application significantly augmented the death
of T98G cells compared to TMZ treatment alone
(Figure 6G). This data supported the idea that inhib-
ition of the Na+/K+ pump activity with relatively low
dosages of ouabain could increase the susceptibility
of the drug-resistant T98G cells to TMZ.
Knockdown of the Na+/K+-ATPase α3 subunit sensitizes
drug resistant T98G cells to TMZ
Due to the marked high expression of the Na+/K+-ATPase
α3 subunit in T98G cells compared to LN229 and
Figure 5 Ouabain-induced ultrastructual features of hybrid cell death in LN229 cells. Electron microscopy was applied to examine the
ultrastructual features of ouabain damaged glioblastoma cells. The lower panel is magnified images. Control cells showed intact plasma
membranes, intact mitochondrial (arrows) and other organelles. Ouabain exposure (24 hrs) resulted in apparent necrotic changes such as
breakdown of the plasma membrane, cytoplasmic swelling, appearance of large and empty vacuoles (arrow head), which is possibly an indication
of autophagic activity. There were also signs of apoptotic pathology such as fragmented and shrinking mitochondria surrounded by the intact
membrane (thick arrows), and acondensed/fragmented nucleus (*). Note that there was nuclear shrinkage in the absence of cell shrinkage, which
is another sign of hybrid cell death.
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http://www.biomedcentral.com/1471-2407/14/716astrocytes, we tested a possible relationship between
Na+/K+-ATPase and TMZ sensitivity. To knockdown
the Na+/K+-ATPase α3 subunit in T98G cells, cells
were treated with stealth RNAi for 48 hrs to reduce the
α3 subunit (Figure 7A). When tested in α3 subunit
knockdown T98G cells, TMZ (100 μM, 48 hrs) caused
significantly more cell death compared to control
T98G cells or α3 knockdown T98G cells without TMZ
exposure (Figure 7B). Western blot analysis showed
that down regulation of the α3 subunit augmented
cytochrome C release from mitochondria to the cytoplasm
when cells were treated with TMZ (Figure 7C and D). On
the other hand, translocation of AIF was not affected by
this knockdown (Figure 7C).
Discussion
The present investigation shows for the first time in cancer
cells that blocking or down regulation of Na+/K+-ATPase
induces a cell death phenotype that has characteristics of
both apoptosis and necrosis. We show that disruption of
K+ homeostasis is a key factor in the induction of apop-
tosis in human glioblastoma cells. Contrary to what is
widely believed that a cell may either die from apoptosis
or necrosis, ouabain induced cell death does not have typ-
ical features of apoptosis or necrosis. Although strong
apoptotic features such as phosphatidylserine transloca-
tion, caspase activation and Bcl-2 reduction were detected,
ouabain-induced cell death in these cells exhibited necroticfeatures as well, including cell swelling, mitochondrial
injury, [Ca2+]i increase, deteriorated cellular organelles
and breakdown of the plasma membrane. Consistent
with the multifaceted ionic changes, ultrastructural al-
terations include both necrotic and apoptotic features.
Since much higher expression of the Na+/K+-ATPase
α2/α3 subunits exists in drug-resistant glioblastoma
cells compared to drug-sensitive and normal human
glial cells, our data indicate that the α2 and/or α3 sub-
units are potential targets for anti-cancer treatments.
This was demonstrated by the different ouabain induced
dose-responses of TMZ-sensitive LN229 cells, TMZ-
resistant T98G cells and normal human astrocytes. This
principle was also specifically demonstrated in the subunit
knockdown experiment. Furthermore, the hybrid cell
death mechanism of multiple targets helped to overcome
the TMZ resistance of glioblastoma cells. Taken together,
this investigation provides a better understanding of the
ionic and cellular mechanisms underlying ouabain-induced
cell death in human glioblastoma cells and suggests a po-
tential therapeutic target for glioblastoma treatment.
We noticed that ouabain-induced apoptotic changes in
LN229 cells were not typical of those caused after valino-
mycin exposure. For example, valinomycin caused gradual
and progressive cell volume shrinkage while ouabain did
not show the same volume change. Instead of apoptotic
cell shrinkage, ouabain causes an initial cell swelling
followed by a gradual decrease in cell volume. According
Figure 6 Expression of Na+/K+-ATPase subunits in LN229/T98G cells and human astrocytes. The expression of Na+/K+-ATPase three α
subunits was detected using reverse transcriptase PCR analysis in glioblastoma cell lines LN229 and T98G as well as in human astrocytes.
A. RT-PCR result shows different mRNA levels of α1, α2 and α3 subunits in the three cell types. Ribosomal protein-19 (RPL-19) was measured as a
housekeeper gene for loading control. B. Quantified data in the bar graph show that T98G cells express higher α1 mRNA levels compared to
LN229 cells but there is no difference in α1 mRNA levels compared to human astrocytes. N = 3 in each group; * P < 0.05 vs. human astrocytes;
# P < 0.05 vs. LN229 cells. C and D. Quantified RT-PCR data on α2 (C) and α3 (D) subunits. Both subunits were highly expressed in T98G cells and
were significant different from those in LN229 cells and human astrocytes. E. MTT assay of cell viability showed that ouabain treatment (0.1 - 5 μM for
6 hrs) significantly reduced the cell viability in T98G cells compared to LN229 cells. F. MTT assay confirmed a higher resistance of T98G cells to TMZ
(0.01 – 100 μM for 24 hrs) compared to LN229 cells. * P < 0.05 vs. LN229 cells. G. MTT assay showed that co-treatment of ouabain (0.1 μM) and TMZ
(100 μM) for 24 hrs significantly augmented the cell vulnerability to TMZ. * P < 0.05 vs. control, # P < 0.05 vs. TMZ alone.
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Figure 7 Na+/K+-ATPase α3 subunit knockdown sensitized T98G cells to TMZ. To test the hypothesis that the high expression of
Na+/K+-ATPase, especially its α3 subunit, plays a critical role in drug resistance of glioblastoma cells, we targeted the α3 subunit using the RNAi
technique to downregulate its expression in T98G cells. A. RT-PCR assay verified that the α3 subunit was knocked down by the α3 stealth RNAi in
T98G cells. B. Trypan blue cell death assay showed that, compared to control (blank bars), α3 knockdown (filled bars) in the drug-resistant T98G
cells induced a trend of increased cell death even without drug insult. The addition of TMZ (100 μM) for 48 hrs more than doubled cell death in
α3 knockdown T98g cells compared to the TMZ-induced cell death without α3 knockdown. N = 3 for each group. * P < 0.05 vs. controls; # P < 0.05 vs.
TMZ treatment in control cells. C. Western blots of AIF, cytochrome c, β-actin and VDAC in cytosolic and mitochondrial fractions of transfection vehicle
control (lipofactamine) and α3 knockdown cells with or without TMZ. There was no noticeable difference in AIF expression under different conditions
while TMZ appeared to affect cytochrome c levels in the cytosol and mitochondrial compartments. D. Quantitative analysis of the Western blotting
showed that α3 knockdown drastically increased cytochrome c release into the cytosol, while the mitochondrial cytochrome c level decreased in
TMZ-treated α3-knockdown cells. N = 3 independent assays in each group. * P < 0.05 vs. α3 knockdown controls.
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data in this investigation, the initial cell swelling is attrib-
utable to intracellular Na+ and Ca2+ accumulation, while
the gradual volume decrease is associated with the slower
process of intracellular K+ depletion [36]. The early cell
swelling followed by cell volume reduction during ouabain
exposure was analogous to the hybrid cell death model(concurrent apoptosis and necrosis in the same cell) that
we reported before in cortical neurons [41]. The acute
increase in Ca2+/Na+ accompanied with a gradual K+
depletion in glioblastoma cells are consistent with the
unique time-dependent cell volume alterations. The ionic
disruptions also can be linked to necrotic and apoptotic
events in these cells.
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Na+/K+-ATPase in tumor cells in the past few years,
virtually all investigations assume apoptosis is the
underlying mechanism for its anti-cancer effect. In the
effort to identify therapeutic targets, many studies have
focused on the α1 subunit while only very few reports
have looked at the role of the α3 subunit [50]. To
understand the ionic mechanism mediating the anti-
cancer property of cardiac glycosides, many research
reports examined intracellular Na+ accumulation and
the Na+-dependent Ca2+ increases (e.g. Ca2+ oscillations)
via enhanced reverse operation of the Na+/Ca2+ exchanger
[31-33]. This research focus, however, overlooks the most
abundant intracellular cation K+ and disregards the K+
role in apoptotic cell volume regulation and in the induc-
tion of apoptotic cascade. This was most likely due to the
influence of many early investigations that simply linked
K+ gradient to membrane potential regulation and the
consequent influence on Ca2+ influx [42]. Accumulating
evidence in recent years, however, has endorsed that a
pro-apoptotic K+ efflux is an integrated cellular event in
the early stage of apoptosis in non-cancerous neuronal,
glial and peripheral cells [34-36]. We now show new
evidence that this K+-mediated apoptotic mechanism
similarly takes place in glioblastoma cells.
In the present investigation, low concentrations of
ouabain and the induced hybrid cell death mechanism
effectively sensitize drug-resistant glioblastoma cells to
the anti-cancer effect of TMZ. It is important to note that,
in this anti-cancer strategy, only a low concentration of
ouabain is needed to sensitize the drug-resistant cancer
cells. At the level of Na+/K+ pump down-regulation,
survival of normal neuronal cells or even drug-sensitive
glioblastoma cells are not affected. This is most likely
due to the fact that expression of Na+/K+-ATPase is
selectively and markedly higher in drug-resistant cells as
shown in T98G cells. This selectivity supports a possible
clinical significance of targeting Na+/K+-ATPase in glio-
blastoma treatment. Moreover, ouabain can pass through
the blood brain barrier [51], which facilitates clinical appli-
cations of ouabain-like drugs in the potential treatment
for brain tumors.
We previously showed that the sublethal low concen-
tration of ouabain (0.1 μM) could markedly enhance the
vulnerability of neuronal cells to pathological insults of
glutamate, ceramide and β-amyloid [43]. The present study
further suggests that ouabain and likely other cardiac glyco-
sides can sensitize glioblastoma cells to conventional
chemotherapy drugs via activation of multiple cell death
mechanisms. While most cytotoxic anticancer drugs in-
cluding alkylating agents such as TMZ have been shown
to induce apoptosis [52], cancer cells could potentially
be targeted by other death mechanisms such as necro-
sis, autophagy, senescence, or mitotic catastrophe [53].To overcome the resistance of glioblastoma cells to TMZ,
it has been postulated that it is possible to combine TMZ
with other drugs to enhance glioblastoma cell response to
TMZ cytotoxicity. In a randomized and double-blind trial
for glioblastoma multiforme, adding chloroquine to con-
ventional treatment including TMZ showed mediocre re-
sults, probably because of the small sample size [54].
Other combination regimens include adding epigallocate-
chin gallate (EGCG) and oxygen-diffusion enhancing
trans-sodium crocetinate (TSC); the later is now in phase
I/II clinical trials [55,56].
In recent years, the mixed form of cell death of similar
or partly overlapped definitions have been reported and
are given different names such as aponecrosis and
necroptosis [57-59]. We prefer the term hybrid death
since it covers different known and novel cell death
mechanisms. While the results from this investigation
are encouraging, we acknowledge the need for further
experiments to fully characterize the nature of cell death
and delineate the detail dose–response relationship of
Na+/K+-ATPase activity and viability of glioblastoma
cells. As an in vitro investigation, our data provide some
initial mechanistic information. The in vivo verification
of the mechanism in an anti-cancer therapy will be essen-
tial. In addition to ouabain, application of other cardiac
glycosides in the anti-cancer treatment should be tested
since these clinical drugs have been used for the treatment
of congestive heart failure and cardiac arrhythmia for
many years. In addition to its effect on ionic homeostasis,
Na+/K+-ATPase has been proposed to have a distinct
function of directly regulating a number of intracellular
signaling pathways [60]. Regulation of these signals may
have important impacts on cell viability status and con-
tribute to the anti-cancer effect of Na+/K+-ATPase inhib-
ition. For example, it will be interesting to investigate the
role of the PI3K/Akt/mTOR pathway that is regulated by
Na+/K+-ATPase and which plays a major role in cancer
cell survival [61].
Conclusion
In using ouabain as a representative Na+/K+-ATPase
inhibitor, this study demonstrates the induction of hy-
brid cell death in glioblastoma cells and enhanced cell
death of a TMZ-resistant cancer cell line. Based on its high
expression level in TMZ-resistance cells, Na+/K+-ATPase
may be a therapeutic target for the treatment of glioblast-
oma and sensitizing glioblastoma cells to conventional
chemotherapy.
Additional files
Additional file 1: Figure S1. Valinomycin-induced apoptotic death of
LN229 cells. Western blotting and immunohistochemistry were applied to
examine the effect of valinomycin on LN229 cells. A. Western blots of
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http://www.biomedcentral.com/1471-2407/14/716Bcl-2, caspase-3 and caspase-9 at 6, 12 and 24 hrs after valinomycin
(10 μM) treatment. B to D. Valinomycin treatment significantly increased
caspase-3 and caspase-9 expression and reduced the anti-apoptotic
protein Bcl-2 expression in LN229 treated cells. N = 3 in each group.
* P < 0.05 vs. vehicle control (CTL). E. Immunohistochemical staining for
apoptosis inducing factor (red) and nuclei (Hoechst, blue) showed that
valinomycin induced AIF translocation from cytoplasm to nucleus 6 hrs
after valinomycin treatment.
Additional file 2: Figure S2. Ouabain-induced cellular Na+ and Ca2+
changes in LN229 cells. Intracellular Na+ and Ca2+ was assessed in LN229
cells using the Na+ dye SBFI-AM and Ca2+ fluorescent dye Fluo-4 AM,
respectively. A and B. SBFI-AM fluorescent imaging showed a gradual
increase in the intracellular Na+ content. B is the quantified analysis of
Na+ imaging showing ouabain-induced acute increase in intracellular Na+
content of LN229 cells within 5–60 min after application of ouabain.
C. Fluo-4-AM imaging detected [Ca2+]i increases in LN229 cells 1 to 3 hrs
after application of 1 μM ouabain. Co-applied BAPTA-AM (1 μM) effectively
prevented the [Ca2+]i change. D. The intensity of Fluo-4 fluorescence was
quantified using Image J software (NIH). Ouabain doubled the [Ca2+]i at
3 hrs after exposure and the Ca2+ level was gradually subsided. N = 240 cells
from 3 independent assays. *p < 0.01 vs. time 0. E. MTT assay showed
that although oubain (1 μM, 24 hrs) reduced cell viability of LN229 cells,
the addition of BAPTA-AM did not show a significant protection on
ouabain-induced cell death. As an intracellular Ca2+ chelator, BAPTA-AM
alone showed some toxicity to LN229 cells. N = 3 independent assays.
* P < 0.01 vs. control.
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